BNTC logo

BENITEC BIOPHARMA INC

BNTCNASDAQ
🏆 #3278 by market capUS Equity
$9.77▼ $0.23 (−2.40%)
Market closed · at close
🔔
Track BNTC
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.4%
7d▼ 0.5%
14d▼ 12.2%
30d▼ 20.0%
ytd▼ 27.5%
1y▼ 28.6%
🏦Market Cap
$336M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
100.0%
High
💵FCF Margin
—
⚖️P/S Ratio
4888.6x
Expensive
Otter Score
44
Weak

Trading Snapshot

Day Range
$9.62 – $9.93
52-Week Range
$9.26 – $16.76
Volume
$4.44B
Avg Volume
$3.24B
Shares Outstanding
34.4M
Next Earnings
Nov 26, 2026

Fundamentals Snapshot

Annual Revenue
$69,572
Last Q Revenue
$17,310
P/E Ratio
—
P/S Ratio
4888.6x
EPS (TTM)
$-1.11
Dividend Yield
—
Dilution (1yr)
+1.3%

Why Investors Own BNTC

  • ✓High-growth profile — revenue up -6.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 30% gross margin and 5% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BNTC logo

BENITEC BIOPHARMA INC

BNTC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +14.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$51M▲ +22.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$17M▼ −29.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
46.6M▲ +1.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$179M▼ −$9M YoY
StockOtter · stockotter.space

About BENITEC BIOPHARMA INC

Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Price Target

ⓘ
Average Target
$10.35
▲ +6.0% Upside
High Target$12.28
Low Target$8.36
Based on 23 analysts

Latest News & Updates

🚀
Barron’s·2h ago

BENITEC BIOPHARMA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift BNTC price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

BENITEC BIOPHARMA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.